Allogene upgraded to Outperform from Market Perform at Citizens JMP
Citizens JMP analyst Reni Benjamin upgraded Allogene Therapeutics (ALLO) to Outperform from Market Perform with a $5 price target The firm ...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ...